Table 3.
Circulating levels of tenascin-C (TNC) do not correlate with any traditional biomarkers of disease in rheumatoid arthritis (RA)
| Cohort | Biomarker | Correlation with TNC at baseline? |
|---|---|---|
| Cohort A | CRP | No |
| Anti-CCP | No | |
| ESR | No | |
| Markers of bone and cartilage metabolism: COMP, CPII, C2C, PIIINP, hyluronan | No | |
| Clinical score: TJC, SJC | No | |
| Disease activity: DAS28 | No | |
| Cohort B | CRP | No |
| Clinical score: TJC, SJC | No | |
| Disease activity: DAS28 | No | |
| Cohort C | CRP | No |
| Anti-CCP | No | |
| Cohort D | N/A | N/A |
TNC levels at baseline (entry into trial) in four separate cohorts of RA patients were analysed by ELISA. CRP, C-reactive protein; anti-CCP, anti-cyclic citrullinated peptide antibody; COMP, cartilage oligomeric matrix protein; CPII, type II pro collagen; C2C, marker of type II collagen cleavage; ESR, erythrocyte sedimentation rate; PIIINP, procollagen III N-terminal propeptide; TJC, tender joint count; SJC, swollen joint count; DAS28, disease activity score 28; N/A, data not available.